Primary |
Influenza |
37.0% |
Avian Influenza |
18.1% |
H1n1 Influenza |
18.1% |
Cough |
3.7% |
Drug Use For Unknown Indication |
3.0% |
Product Used For Unknown Indication |
2.7% |
Sedation |
2.4% |
Prophylaxis |
1.9% |
Antiviral Prophylaxis |
1.6% |
Nosocomial Infection |
1.6% |
Antibiotic Therapy |
1.4% |
Anti-infective Therapy |
1.3% |
Pneumonia |
1.1% |
Cerebral Palsy |
1.0% |
Hypovolaemic Shock |
1.0% |
Immunosuppression |
1.0% |
Upper Gastrointestinal Haemorrhage |
1.0% |
Wheezing |
1.0% |
Hypotension |
0.8% |
Acute Coronary Syndrome |
0.6% |
|
Normal Newborn |
29.1% |
Pregnancy |
14.1% |
Pathogen Resistance |
8.4% |
Acute Respiratory Distress Syndrome |
6.9% |
Death |
5.7% |
Pneumonia |
5.5% |
Respiratory Failure |
5.0% |
Drug Ineffective |
3.8% |
Drug Exposure During Pregnancy |
3.6% |
Thrombocytopenia |
2.4% |
Delirium |
1.9% |
Multi-organ Failure |
1.9% |
Sepsis |
1.9% |
Ventricular Septal Defect |
1.9% |
Periproctitis |
1.4% |
Septic Shock |
1.4% |
Vomiting |
1.4% |
Drug Resistance |
1.2% |
Influenza |
1.2% |
Premature Baby |
1.2% |
|
Secondary |
Product Used For Unknown Indication |
36.3% |
Influenza |
10.9% |
Drug Use For Unknown Indication |
10.7% |
H1n1 Influenza |
8.4% |
Prophylaxis |
4.6% |
Immunosuppression |
4.5% |
Avian Influenza |
4.0% |
Foetal Exposure During Pregnancy |
3.3% |
Pneumonia |
3.3% |
Hypertension |
2.5% |
Sedation |
2.2% |
Cholecystitis Acute |
1.2% |
Infection |
1.2% |
Rheumatoid Arthritis |
1.2% |
Mycobacterium Fortuitum Infection |
1.0% |
Sepsis |
1.0% |
Aspergillosis |
0.9% |
Muscle Spasms |
0.9% |
Prophylaxis Against Graft Versus Host Disease |
0.9% |
Upper Gastrointestinal Haemorrhage |
0.9% |
|
Pathogen Resistance |
12.8% |
Drug Ineffective |
9.4% |
Acute Respiratory Distress Syndrome |
7.7% |
Death |
7.7% |
Pneumonia |
7.7% |
Vestibular Disorder |
6.8% |
Multi-organ Failure |
6.0% |
Respiratory Failure |
5.1% |
Influenza |
4.3% |
Torsade De Pointes |
4.3% |
Foetal Distress Syndrome |
3.4% |
Septic Shock |
3.4% |
Shock |
3.4% |
Hepatitis Cholestatic |
2.6% |
Pregnancy |
2.6% |
Renal Impairment |
2.6% |
Sepsis |
2.6% |
Serum Sickness |
2.6% |
Thrombocytopenia |
2.6% |
Toxicity To Various Agents |
2.6% |
|
Concomitant |
Drug Use For Unknown Indication |
27.1% |
Product Used For Unknown Indication |
17.6% |
Multiple Myeloma |
6.3% |
Prophylaxis |
5.8% |
H1n1 Influenza |
5.1% |
Influenza |
4.9% |
Hypertension |
3.7% |
Immunosuppression |
3.0% |
Infection |
3.0% |
Adverse Event |
2.8% |
Evidence Based Treatment |
2.8% |
Mycobacterium Fortuitum Infection |
2.8% |
Pneumonia |
2.6% |
Atrial Fibrillation |
2.3% |
Renal Failure Chronic |
2.1% |
Constipation |
1.9% |
Vasculitis |
1.9% |
Antibiotic Therapy |
1.6% |
Chronic Graft Versus Host Disease |
1.4% |
Pain |
1.4% |
|
Pneumonia |
9.3% |
Respiratory Failure |
7.4% |
Respiratory Tract Infection |
7.4% |
Therapeutic Response Decreased |
7.4% |
Death |
5.6% |
Pyrexia |
5.6% |
Sinus Arrest |
5.6% |
Weight Decreased |
5.6% |
Weight Increased |
5.6% |
White Blood Cell Count Decreased |
5.6% |
Drug Ineffective |
3.7% |
H1n1 Influenza |
3.7% |
Hallucination, Visual |
3.7% |
Liver Injury |
3.7% |
Multi-organ Failure |
3.7% |
Neutropenia |
3.7% |
Pancreatitis |
3.7% |
Sepsis |
3.7% |
Tachycardia |
3.7% |
Abscess Fungal |
1.9% |
|
Interacting |
Atrial Fibrillation |
33.3% |
Product Used For Unknown Indication |
14.3% |
H1n1 Influenza |
9.5% |
Hypertension |
9.5% |
Influenza |
9.5% |
Pyelonephritis |
9.5% |
Cardiac Valve Disease |
4.8% |
Deep Vein Thrombosis |
4.8% |
Pulmonary Embolism |
4.8% |
|
Drug Interaction |
25.0% |
Torsade De Pointes |
25.0% |
Haemoptysis |
16.7% |
International Normalised Ratio Increased |
16.7% |
Ascites |
8.3% |
Vomiting |
8.3% |
|